19 Mar 2020 --- Swiss-based Hochdorf Group has reported it had a “transformative” 2019 amid past acquisitions that did not result in profit. The extension of a syndicated loan and the sale of the Pharmalys companies – acquired in 2016 – were two of the most important measures implemented to stabilize the company. Despite its efforts, the Group reports significant losses as it generated a net sales revenue of CHF 456.8 million (US$465 million) in 2019, which is almost 19 percent down from 2018. Due to the highly negative results, the Board of Directors has proposed to shareholders that no dividend be paid this year and also implement a financially sustainable modus operandi.
